目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T63114 | |||
ALK5-IN-7 是一种 ALK5 的有效抑制剂。转化生长因子 β (TGF-β) 是一种多功能细胞因子,能够利用细胞表面的复杂受体信号通路,通过自分泌、旁分泌和内分泌的方式参与调控细胞增殖、分化和凋亡。ALK5-IN-7 具有潜力进行 TGF-β 相关疾病和病症的研究(包括但不限于肿瘤、纤维化疾病、炎症性疾病、自身免疫性疾病等)。 | |||
T83422 | |||
1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine 是一种由磷酸甘油、胆碱和棕榈酸构成的甘油磷酸胆碱类化合物,通常在体内氧化应激位点累积。该化合物是 B 类清道夫受体 (CD36和SR-BI) 的有效配体,特别是氧化磷脂 oxPC(CD36)。此外,氧化磷脂 (oxPLs) 在肿瘤细胞凋亡中扮演关键角色,并且在恶性胆管狭窄疾病中可能会有所增加。 | |||
T78569 | Apoptosis | ||
CPT2 (Carnitine palmitoyltransferase 2) 是一种脂肪酸氧化过程中的酶,它在结直肠癌 (CRC) 预后评估中作为生物标志物。CPT2 通过过表达激活p-p53并增加p53蛋白水平,这有助于抑制肿瘤生长和促进细胞的凋亡。CPT2 缺乏是长链脂肪酸氧化障碍相关的常见遗传性疾病,并且CPT2 的表达降低与多种癌症的发展密切相关,因此,在癌症研究领域具有研究价值。 | |||
T63664 | |||
CDK/HDAC-IN-2 是有效的 HDAC/CDK 双重抑制剂,能够作用于 HDAC1 (IC50: 6.4 nM)、HDAC2 (IC50: 0.25 nM)、HDAC3 (IC50: 45 nM)、HDAC6,8 (IC50>1000 nM)、CDK1 (IC50: 8.63 nM)、CDK2 (IC50: 0.30 nM)、CDK4,6,7 (IC50>1000 nM)。CDK/HDAC-IN-2 能够将细胞周期停滞在 G2/M 期,并诱导细胞凋亡 (apoptosis)。CDK/HDAC-IN-2 具有优异的抗增殖效果,显示出显著的抗肿瘤作用。 | |||
T81469 | PI3K | ||
PI3Kα-IN-14(复合物F8)是一款高度选择性的PI3Kα抑制剂,其IC50值为0.14 nM 。此化合物能显著降低线粒体膜的完整性,并在U87-MG细胞中引起G1期细胞周期的停滞以及凋亡现象。此外,PI3Kα-IN-14在不同来源的肿瘤细胞系中均展现出明显的抗增殖能力,其中PC-3的IC50为0.28 μM,HCT-116的IC50为0.57 μM,以及U87-MG的IC50为1.37 μM。 | |||
T36888 | |||
9(Z),11(E),13(E)-Octadecatrienoic Acid ethyl ester (α-ESA) is a conjugated polyunsaturated fatty acid commonly found in plant seed oil. This fatty acid accounts for about 60% of the total fatty acid composition of bitter gourd seed oil and about 70% in tung oil. α-ESA is metabolized and converted to conjugated linoleic acid (9Z,11E-CLA) in rats. It has shown potential as a tumor growth suppressor. In colon cancer Caco-2 cells, α-ESA induced apoptosis through up-regulation of GADD45, p53, and PPARγ. In DLD-1 cells supplemented with α-ESA, apoptosis was induced via lipid peroxidation with an EC50 of 20 μM. It also inhibits DNA polymerases and topoisomerases with IC50s ranging from ~5-20 μM for different isoforms of the enzymes. α-ESA ethyl ester is a neutral, more lipid soluble form of the free acid. | |||
T68502 | |||
Dibrospidium Free Base is a dispirotripiperazine derivative and alkylating agent with potential antineoplastic and anti-inflammatory activities. The duration of DNA synthesis inhibition in tumor cells was found to correlate with spirobromine antitumor activity. Spirobromin is superior to prospidin by the power of the anti-inflammatory effect. Spyrobromin can diminish the latent period of the development of tumours in the experimental rats at intraperitoneal administration. At intragastric administration of the drug no decrease was noted in the latent period and no increase of tumours was observed in the experimental groups of the animals as compared with control. Dibrospidium has been examined for the treatment of bone cancer. The oral route of administration is the most safe with respect to the oncogenic risk. It was noted that spirobromin exerted the most pronounced toxic action on erythrocytes. Dibrospidium is used for the treatment of acute leukemias (mainly in combinatio...... | |||
T70128 | |||
Olmutinib is a novel third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor, used in the treatment of T790M mutation positive non-small cell lung cancer. Olmutinib covalently binds a cysteine residue near the kinase domain of mutant EGFRs to prevent phosphorylation of the receptor. EGFRs are frequently over-expressed in lung cancer and contribute to activation of the phosphoinositide 3-kinase and mitogen-activated protein kinase pathways which both promote cell survival and proliferation. By inhibiting EGFR activation, Olmutinib attenuates the activation of these tumor-promoting pathways. In the first phase I/II clinical study of Osimertinib, 800 mg/ day was chosen as the dose for subsequent studies, and the dose-limiting toxicity and maximum tolerated dose was not reached. Olmutinib received breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. | |||
T36085 | |||
PKI-179 is an orally bioavailable dual inhibitor of PI3K and mammalian target of rapamycin (mTOR). In an in vitro enzymatic assay, it potently inhibits PI3K (IC50s = 8, 24, 17, and 74 nM for isoforms α, β, δ, and γ, respectively), two common PI3Kα mutants, E545K and H1047R (IC50s = 14 and 11 nM, respectively), and mTOR (IC50 = 0.42 nM). PKI-179 is selective for PI3K and mTOR over a panel of 361 other kinases at IC50 values up to 50 μM, hERG (IC50 > 30 μM), and cytochrome P450 (CYP) isoforms (IC50s > 30 μM), but does have activity for CYP2C8 (IC50 = 3 μM). It inhibits proliferation through the Akt/mTOR signaling pathway in MDA-361 breast and PC3MM2 prostate cancer cell lines in vitro (IC50s = 22 and 29 nM, respectively) and inhibits tumor growth in an MDA-361 mouse xenograft model when used at a dose of 50 mg/kg. | |||
T36461 | |||
CAY10748 is an agonist of stimulator of interferon genes (STING; IC50= 0.3794 μM in a competition binding assay).1It activates STING in STING-expressing, but not STING knockout, THP-1 cells (EC50s = 0.287 and >100 μM, respectively, in a reporter assay). It induces phosphorylation of STING at the serine in position 366, as well as phosphorylation of TBK1 and IFN regulatory factor 3 (IRF3), indicating activation of the STING-TBK1-IRF3 signaling pathway. CAY10748 increases the secretion of IFN-β and the levels of chemokine (C-X-C motif) ligand 10 (CXCL10), and IL-6 in peripheral blood mononuclear cells (PBMCs) when used at a concentration of 10 μM. It also reduces tumor growth in a CT26 murine colon cancer model when administered at a dose of 0.15, but not 1.5, mg/kg. 1.Xi, Q., Wang, M., Jia, W., et al.Design, synthesis, and biological evaluation of amidobenzimidazole derivatives as stimulator of interferon genes (STING) receptor agonistsJ. Med. Chem.63(1)260-282(2019) |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-05153 | TROP-2 Protein, Cynomolgus, Rhesus, Recombinant (His) | Cynomolgus,Rhesus | HEK293 Cells | ||
TROP-2 Protein, Cynomolgus, Rhesus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 28.7 kDa and the accession number is XP_001114599.1.
|
|||||
TMPY-01429 | RELT/TNFRSF19L Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
RELT/TNFRSF19L Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 15.7 kDa and the accession number is A0A024R5N3.
|
|||||
TMPY-03101 | TNFR2/CD120b/TNFR1B Protein, Cynomolgus, Rhesus, Recombinant (His) | Cynomolgus,Rhesus | HEK293 Cells | ||
TNFR2/CD120b/TNFR1B Protein, Cynomolgus, Rhesus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.5 kDa and the accession number is XP_005544817.1&NP_001253134.1.
|
|||||
TMPY-03645 | BAFF/TNFSF13B Protein, Cynomolgus, Recombinant (hFc) | Cynomolgus | HEK293 Cells | ||
BAFF/TNFSF13B Protein, Cynomolgus, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 38.1 kDa and the accession number is F7H548.
|
|||||
TMPY-04289 | CD30L Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
CD30L Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 22 kDa and the accession number is G7P2F1.
|
|||||
TMPY-05504 | 4-1BB/CD137/TNFRSF9 Protein, Rhesus, Recombinant (His), Biotinylated | Rhesus | HEK293 Cells | ||
4-1BB/CD137/TNFRSF9 Protein, Rhesus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 18.7 kDa and the accession number is XP_005544945.1&NP_001253057.1.
|
|||||
TMPY-03213 | BCMA/TNFRSF17 Protein, Rhesus, Recombinant (hFc) | Rhesus | HEK293 Cells | ||
BCMA/TNFRSF17 Protein, Rhesus, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 33 kDa and the accession number is A0A2K5UD97.
|
|||||
TMPY-02202 | TNF alpha Protein, Rat, Recombinant | Rat | E. coli | ||
TNF alpha Protein, Rat, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 17.4 kDa and the accession number is P16599.
|
|||||
TMPY-04146 | TNF alpha Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
TNF alpha Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 45.8 kDa and the accession number is P01375.
|
|||||
TMPJ-00779 | TNF alpha Protein, Rabbit, Recombinant | Rabbit | E. coli | ||
Tumor necrosis factor alpha (TNFα) is the prototypic ligand of the TNF superfamily. TNFα forms a homotrimer and functions by activating two types of receptors TNF-R1 (TNF receptor type 1,p55R) and TNF-R2 (TNF receptor type 2,p75R). TNFα is a pleiotropic cytokine that is capable to promote inflammation, to induce apoptotic cell death, and to inhibit tumorigenesis and viral replication. TNFα is a potent lymphoid factor that exerts cytotoxic effects on a wide range of tumor cells and certain other target cells.
|
|||||
TMPY-00705 | CD30L Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
CD30L Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 47.8 kDa and the accession number is P32971.
|
|||||
TMPJ-00139 | 4-1BB Ligand/TNFSF9 Protein, Human, Recombinant (His) | Human | E. coli | ||
4-1BB Ligand/TNFSF9 Protein, Human, Recombinant (His) is expressed in E. coli expression system with C-6xHis tag. The predicted molecular weight is 16-20 KDa and the accession number is P41273.
|
|||||
TMPY-05568 | BCMA/TNFRSF17 Protein, Human (His & hFc), PE conjugated | Human | HEK293 Cells | ||
BCMA/TNFRSF17 Protein, Human (His & hFc), PE conjugated is expressed in HEK293 mammalian cells with His and Fc tag. The accession number is NP_001183.2.
|
|||||
TMPY-04645 | TL1A/TNFSF15 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
TL1A Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 48.9 kDa and the accession number is A0A0U5JA19.
|
|||||
TMPY-05319 | BCMA/TNFRSF17 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
BCMA/TNFRSF17 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 7.3 kDa and the accession number is Q02223-1.
|
|||||
TMPY-01827 | CD30/TNFRSF8 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
CD30/TNFRSF8 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 40 kDa and the accession number is P28908-1.
|
|||||
TMPY-00936 | TNF alpha Protein, Human, Recombinant | Human | E. coli | ||
TNF alpha Protein, Human, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 17.5 kDa and the accession number is P01375.
|
|||||
TMPY-05594 | 4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc & Avi), Biotinylated | Human | HEK293 Cells | ||
4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with hFc and Avi tag. The predicted molecular weight is 45.8 kDa and the accession number is Q07011.
|
|||||
TMPY-04493 | BCMA/TNFRSF17 Protein, Human, Recombinant (rFc) | Human | HEK293 Cells | ||
BCMA/TNFRSF17 Protein, Human, Recombinant (rFc) is expressed in HEK293 mammalian cells with rFc tag. The predicted molecular weight is 33.3 kDa and the accession number is Q02223-1.
|
|||||
TMPY-01743 | 4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 18.8 kDa and the accession number is Q07011.
|
|||||
TMPY-05376 | 4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 44 kDa and the accession number is Q07011.
|
|||||
TMPY-00072 | GITR/TNFRSF18 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
GITR/TNFRSF18 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 16 kDa and the accession number is Q9Y5U5-3.
|
|||||
TMPY-00033 | 4-1BB Ligand/TNFSF9 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
4-1BB Ligand/TNFSF9 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 47.9 kDa and the accession number is A0A0U5J8I0.
|
|||||
TMPY-02667 | TROP-2 Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
TROP-2 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 29.4 kDa and the accession number is Q8BGV3.
|
|||||
TMPY-02726 | RANKL/TNFSF11/CD254 Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 Cells | ||
RANKL/TNFSF11/CD254 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 56 kDa and the accession number is AAC40113.1.
|
|||||
TMPJ-01466 | Osteoprotegerin Protein, Human, Recombinant (aa 22-401, His) | Human | HEK293 Cells | ||
TNFRSF11B is a secreted protein, containing 2 death domains and 4 TNFR-Cys repeats. TNFRSF11B is a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL). By binding RANKL, TNFRSF11B inhibits nuclear kappa B (NF-κB) which is a central and rapid acting transcription factor for immune-related genes, and a key regulator of inflammation, innate immunity, and cell survival and differentiation. TNFRSF11B levels are influenced by voltage-dependent calcium channelsCav1.2. TNFRSF11B can reduce the production of osteoclasts by inhibiting the differentiation of osteoclast precursors (osteoclasts are related to monocytes/macrophages and are derived from granulocyte/macrophage-forming colony units (CFU-GM)) into osteoclasts and also regulates the resorption of osteoclasts in vitroand in vivo. TNFRSF11B binding to RANKL on osteoblast/stromal cells, blocks the RANKL-RANK ligand interaction between osteoblast/stromal cells and osteoclast precursors. This has the effect of inhibiting the differentiation of the osteoclast precursor into a mature osteoclast.
|
|||||
TMPY-01750 | HVEM Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
HVEM Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 19 kDa and the accession number is A0A024R052.
|
|||||
TMPY-01423 | OX40/TNFRSF4 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
OX40/TNFRSF4 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 21.7 kDa and the accession number is P43489.
|
|||||
TMPY-01294 | TNF alpha Protein, Mouse, Recombinant | Mouse | E. coli | ||
TNF alpha Protein, Mouse, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 17.39 kDa and the accession number is P06804.
|
|||||
TMPJ-00994 | LTBR Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 Cells | ||
It is a single-pass type I membrane protein and contains 4 TNFR-Cys repeats. The protein is a member of the tumor necrosis factor (TNF) family of receptors. It is expressed on the surface of most cell types, including cells of epithelial and myeloid lineages, but not on T and B lymphocytes. The protein is the receptor for the heterotrimeric lymphotoxin containing LTA and LTB, and for TNFS14/LIGHT. It promotes apoptosis via TRAF3 and TRAF5 and may play a role in the development of lymphoid organs. The encoded protein and its ligand play a role in the development and organization of lymphoid tissue and transformed cells. Activation of the encoded protein can trigger apoptosis. Not only does the TNFRSF3 help trigger apoptosis, it can lead to the release of the cytokine interleukin 8. Overexpression of TNFRSF3 in Human Cells cells increases IL-8 promoter activity and leads to IL-8 release. TNFRSF3 is also essential for development and organization of the secondary lymphoid organs and chemokine release.
|
|||||
TMPY-04832 | OX40L/TNFSF4 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
OX40L/TNFSF4 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 46.6 kDa.
|
|||||
TMPY-02096 | TACI Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
TACI Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 14.8 kDa and the accession number is O14836-2.
|
|||||
TMPH-02975 | Wilms tumor protein homolog Protein, Mouse, Recombinant (His & Myc) | Mouse | E. coli | ||
Wilms tumor protein homolog Protein, Mouse, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 56.7 kDa and the accession number is P22561.
|
|||||
TMPY-05767 | 4-1BB/CD137/TNFRSF9 Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
4-1BB/CD137/TNFRSF9 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 19.00 kDa and the accession number is P20334.
|
|||||
TMPY-04722 | DcR1/TRAILR3 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
TNFRSF10C CNV in patients with CRC is associated with distant metastatic disease. A high frequency of CGI methylation in the TNFRSF10C promoter results in inactivation of the gene and enhancement of tumor growth in most PC cell lines (except CFPAC-1). Inactivation of TNFRSF10C by CpG island (CGI) hypermethylation can play an important role in PC progression and be potentially useful as a diagnostic marker and a new therapeutic approach for PC.
|
|||||
TMPY-01262 | TROP-2 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
TROP-2 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 29.4 kDa and the accession number is P09758.
|
|||||
TMPY-03364 | RANKL/TNFSF11/CD254 Protein, Human, Recombinant | Human | HEK293 Cells | ||
RANKL/TNFSF11/CD254 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 20.5 kDa and the accession number is AAC51762.1.
|
|||||
TMPY-03674 | RANKL/TNFSF11/CD254 Protein, Human, Recombinant (mFc) | Human | HEK293 Cells | ||
RANKL/TNFSF11/CD254 Protein, Human, Recombinant (mFc) is expressed in HEK293 mammalian cells with mFc tag. The predicted molecular weight is 52.4 kDa and the accession number is AAC51762.1.
|
|||||
TMPH-02312 | Wilms tumor protein/WT1 Protein, Human, Recombinant (His & SUMO) | Human | E. coli | ||
Transcription factor that plays an important role in cellular development and cell survival. Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'. Regulates the expression of numerous target genes, including EPO. Plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. Function may be isoform-specific: isoforms lacking the KTS motif may act as transcription factors. Isoforms containing the KTS motif may bind mRNA and play a role in mRNA metabolism or splicing. Isoform 1 has lower affinity for DNA, and can bind RNA.
|
|||||
TMPY-04142 | RANK/TNFRSF11A Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
RANK/TNFRSF11A Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 46.8 kDa and the accession number is Q9Y6Q6-3.
|
|||||
TMPY-01920 | BAFF/TNFSF13B Protein, Human, Recombinant (HEK293) | Human | HEK293 Cells | ||
BAFF/TNFSF13B Protein, Human, Recombinant (HEK293) is expressed in HEK293 mammalian cells. The predicted molecular weight is 17 kDa and the accession number is Q9Y275-1.
|
|||||
TMPY-05365 | BAFF/TNFSF13B Protein, Human, Recombinant (Avi & Fc), Biotinylated | Human | HEK293 Cells | ||
BAFF/TNFSF13B Protein, Human, Recombinant (Avi & Fc), Biotinylated is expressed in HEK293 mammalian cells with AVI and Fc tag. The predicted molecular weight is 45.6 kDa and the accession number is A0A0U5J7Q1.
|
|||||
TMPJ-00147 | FOLR1 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
FOLR1 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with C-Fc tag. The predicted molecular weight is 55-75 kDa and the accession number is P15328.
|
|||||
TMPJ-00603 | TL1A/TNFSF15 Protein, Mouse, Recombinant | Mouse | E. coli | ||
Tumor Necrosis Factor Ligand Superfamily Member 15 (TNFSF15) is a new member of the tumor necrosis factor family. TNFSF15 is predominantly an endothelial cell-specific gene, and recombinant TNFSF15 is a potent inhibitor of endothelial cell proliferation, angiogenesis and tumor growth. TNFSF15 exerts two activities on endothelial cells: early G1 arrest of G0/G1-cells responding to growth stimuli and programmed cell death of proliferating cells. These activities are highly specific to endothelial cells. TNFSF15 is also able to regulate the expression of several important genes involved in angiogenesis. These findings are consistent with the view that TNFSF15 functions as an autocrine cytokine to inhibit angiogenesis and stabilize the vasculature.
|
|||||
TMPY-01166 | TNFR2/CD120b/TNFR1B Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
TNFR2/CD120b/TNFR1B Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.6 kDa and the accession number is P20333-1.
|
|||||
TMPY-01185 | DR5/TRAIL R2 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
DR5/TRAIL R2 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 15.7 kDa and the accession number is O14763-1.
|
|||||
TMPJ-00280 | TNF R1 Protein, Mouse, Recombinant | Mouse | E. coli | ||
Tumor necrosis factor receptor superfamily member 1A (Tnfrsf1a) is a member of the tumor necrosis factor receptor superfamily. Tnfrsf1a is one of the major receptors for the tumor necrosis factor-alpha. It can activate the transcription factor NF-κB, mediate apoptosis, and function as a regulator of inflammation. Antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRADD and TRAF2 have been shown to interact with this receptor, and thus play regulatory roles in the signal transduction mediated by the receptor. Germline mutations of the extracellular domains of this receptor were found to be associated with the human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS) or periodic fever syndrome
|
|||||
TMPY-02228 | p53 Protein, Cynomolgus, Recombinant | Cynomolgus | E. coli | ||
p53, also known as Tp53, is a DNA-binding protein which belongs to the p53 family. It contains transcription activation, DNA-binding, and oligomerization domains. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 (TP53) is a transcription factor whose protein levels and post-translational modification state alter in response to cellular stress (such as DNA damage, hypoxia, spindle damage). Activation of p53 begins through a number of mechanisms including phosphorylation by ATM, ATR, Chk1 and MAPKs. MDM2 is a ubiquitin ligase that binds p53 and targets p53 for proteasomal degradation. Phosphorylation, p14ARF and USP7 prevent MDM2-p53 interactions, leading to an increase in stable p53 tetramers in the cytoplasm. Further modifications such as methylation and acetylation lead to an increase in Tp53 binding to gene specific response elements. Tp53 regulates a large number of genes (>100 genes) that control a number of key tumor suppressing functions such as cell cycle arrest, DNA repair, senescence and apoptosis. Whilst the activation of p53 often leads to apoptosis, p53 inactivation facilitates tumor progression. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Defects in TP53 are a cause of esophageal cancer, Li-Fraumeni syndrome, lung cancer and adrenocortical carcinoma.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-02402 | WTAP Protein, Human, Recombinant (GST) | Human | E. coli | ||
Wilms' tumor 1-associating protein (WTAP) was previously identified as a protein associated with Wilms' tumor-1 (WT-1) protein that is essential for the development of the genitourinary system. WT1 was originally identified as a tumor suppressor for Wilms' tumor, but it is also overexpressed in a variety of cancer cells. The WTAP-WT1 axis in vascular cells suggest that WTAP is a vital and multifaceted regulator of vascular remodeling. WTAP has been suggested to function in alternative splicing, stabilization of mRNA, and cell growth. Knocking down endogenous WTAP increased Smooth muscle cells (SMCs) proliferation, because of increased DNA synthesis and G(1)/S phase transition, together with reduced apoptosis. These effects could be the result of WTAP suppressing the transcriptional activity of WT1 in SMCs. WTAP may thus also play a role in messenger RNA processing in mammalian cells, either dependent on or independent of its interaction with WT1.
|
|||||
TMPY-05152 | TROP-2 Protein, Rat, Recombinant (His) | Rat | HEK293 Cells | ||
TROP-2 Protein, Rat, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 29.5 kDa and the accession number is A0A0G2JSJ1.
|